Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADA | P00813 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662651 | 0.81 | PIK3CG (0.38) | — | |
| SCHEMBL16662380 | 0.79 | ADORA2A (0.35) | CSNK2A1ADORA2AADORA1LMNAADORA2B | |
| SCHEMBL18685172 | 0.76 | RECQL (0.37) | LMNA | |
| SCHEMBL1662829 | 0.75 | MEN1 (0.46) | LMNAKDR | |
| SCHEMBL31322925 | 0.73 | ADORA2A (0.30) | ADORA2AADORA1 | |
| SCHEMBL31714256 | 0.73 | KDR (0.34) | ADORA2AADORA1ADORA2BKDR | |
| SCHEMBL26643768 | 0.72 | FFAR1 (0.35) | ADORA2AADORA1ADORA2B | |
| SCHEMBL22245124 | 0.70 | CSNK2A1 (0.33) | CSNK2A1 | |
| SCHEMBL22118795 | 0.70 | CSNK2A1 (0.33) | CSNK2A1 | |
| SCHEMBL21960865 | 0.70 | MAP3K14 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3071570-A1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Pfizer Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| WO-2015075598-A1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015075598-A1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141402-A1 | PURINE DERIVATIVES | ADORA3, ADORA1, HPRT1 | CSNK2A1 3342/4885BRD4 2005/4885ADORA2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.